Analgesic efficacy andsafety comparison of different doses of remifentanil for postoperative children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007189

Enrollment

Unknown

Registered

2015-10-09

Start date

2015-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative children

Interventions

RF1:continuous intravenous infusion of remifentanyl 1ug/kg·h andmidazolam 2ug/kg·min

RF2:continuous intravenous infusion of remifentanyl 3ug/kg·h andmidazolam 2ug/kg·min

RF3:continuous intravenous infusion of remifentanyl 6ug/kg·h andmidazolam 2ug/kg·min

SF:continuous intravenous infusion of sufentanyl 0.08ug/kg·h andmidazolam 2ug/·kg·min

M:continuous intravenous infusion of morphine 20ug/kg·h andmidazolam 2ug/kg·min

RF4:continuous intravenous infusion of remifentanyl 9ug/kg·h andmidazolam 2ug/kg·min

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To collect 180 cases of children in PICU, including ASA sizing I - II level of surgery patients, including cardiothoracic surgery patients, brain surgery patients after operation, postoperative orthopaedic surgery patients, andgeneral surgery postoperative patients.

Exclusion criteria

Exclusion criteria: Postoperative pacemakers, complicated by heart failure, infection, postoperative ICU stay time < 8 h

Design outcomes

Primary

Measure	Time frame
faces pain scale;Ramsay score;	—

Secondary

Measure	Time frame
heart rate;heart rate;mean aterial pressure;SPO2;lactic acid;blood glucose;serum cortisol;	—

Countries

China

Contacts

Public ContactFeng Xu

xufeng9899@163.com+023 63622664

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026